Table 1 Clinicopathologic features among 18 patients for acquired MET amplification
Characteristics | Number | Percentage (%) |
|---|---|---|
Gender | ||
Male | 7 | 38.9 |
Female | 11 | 61.1 |
Age (years) | ||
Mean | 57Â years | Â |
< 60 | 10 | 55.6 |
≥ 60 | 8 | 44.4 |
ECOG PS | ||
0–1 | 18 | 100 |
2 | 0 | 0 |
Histologic type | ||
Adenocarcinoma | 16 | 88.9 |
Other | 2 | 11.1 |
Smoking status | ||
No | 12 | 66.7 |
Yes | 6 | 33.3 |
Type of EGFR mutation | ||
19 deletion | 2 | 11.1 |
21L858R | 16 | 88.9 |
Type of EGFR-TKIs | ||
Gefitinib | 10 | 55.6 |
Elrotinib | 3 | 16.7 |
Icotinib | 5 | 27.8 |
Treatment lines of EGFR-TKI | ||
First line | 12 | 66.7 |
Second line or more | 6 | 33.3 |
Met amplification | ||
> 5 | 12 | 66.7 |
2.2–5 | 4 | 22.2 |
1.8–2.2 | 2 | 11.1 |
Receiving crizotinib | ||
Yes | 14 | 77.8 |
No | 4 | 22.2 |